Search research articles
Contact Us
Filters
Showing results (31-40 of 80) with videos related to
Page
of 8
Sort By:
JCO Precision Oncology
|
October 7, 2024
Response to Crizotinib After Entrectinib Resistance in <i>ROS1</i>-Rearranged, <i>MET</i>-Amplified Lung Adenocarcinoma
Victor R Vaz, Malini M Gandhi, Biagio Ricciuti, et al.
Journal for Immunotherapy of Cancer
|
August 6, 2020
Outcomes to first-line pembrolizumab in patients with PD-L1-high (≥50%) non-small cell lung cancer and a poor performance status
Joao V Alessi, Biagio Ricciuti, Elizabeth Jiménez-Aguilar, et al.
Journal for Immunotherapy of Cancer
|
December 21, 2025
Multi-omics analysis reveals differential benefits of immunotherapy±chemotherapy based on detailed smoking history in advanced non-small cell lung cancer
Xinan Wang, Biagio Ricciuti, Arielle Elkrief, et al.
JTO Clinical and Research Reports
|
April 20, 2026
Efficacy of Adding Immune Checkpoint Inhibition to Chemotherapy, With or Without VEGF Inhibition, in Patients With Advanced <i>EGFR</i>-Mutated NSCLC: A Systematic Review and Meta-Analysis With Reconstructed Individual Patient Data
Alessandro Di Federico, Sara Stumpo, Linda Danielli, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
April 12, 2021
SMARCA4 and Other SWItch/Sucrose NonFermentable Family Genomic Alterations in NSCLC: Clinicopathologic Characteristics and Outcomes to Immune Checkpoint Inhibition
Joao V Alessi, Biagio Ricciuti, Liam F Spurr, et al.
The Lancet. Oncology
|
October 2, 2025
Long-term overall survival with dual CTLA-4 and PD-L1 or PD-1 blockade and biomarker-based subgroup analyses in patients with advanced non-small-cell lung cancer: a systematic review and reconstructed individual patient data meta-analysis
Alessandro Di Federico, Sara Stumpo, Francesco Mantuano, et al.
JCO Precision Oncology
|
February 8, 2024
Association of Baseline Tumor-Specific Neoantigens and CD8<sup>+</sup> T-Cell Infiltration With Immune-Related Adverse Events Secondary to Immune Checkpoint Inhibitors
Csaba Kerepesi, Hassan Mohammed Abushukair, Biagio Ricciuti, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
January 26, 2025
Gene Copy Deletion of STK11, KEAP1, and SMARCA4: Clinicopathologic Features and Association With the Outcomes of Immunotherapy With or Without Chemotherapy in Nonsquamous NSCLC
Malini M Gandhi, Arielle Elkrief, Catherine Gutierrez Moore, et al.
Cell Reports. Medicine
|
October 15, 2025
Pan-cancer spatial characterization of key immune biomarkers in the tumor microenvironment
James R Lindsay, Jennifer Altreuter, Joao V Alessi, et al.
Journal for Immunotherapy of Cancer
|
November 26, 2021
Low peripheral blood derived neutrophil-to-lymphocyte ratio (dNLR) is associated with increased tumor T-cell infiltration and favorable outcomes to first-line pembrolizumab in non-small cell lung cancer
Joao V Alessi, Biagio Ricciuti, Stephanie L Alden, et al.
Page
of 8
Search research articles
Search
Showing results (31-40 of 80) with videos related to
Sort By:
Page
of 8
JCO Precision Oncology
|
October 7, 2024
Response to Crizotinib After Entrectinib Resistance in <i>ROS1</i>-Rearranged, <i>MET</i>-Amplified Lung Adenocarcinoma
Victor R Vaz, Malini M Gandhi, Biagio Ricciuti, et al.
Journal for Immunotherapy of Cancer
|
August 6, 2020
Outcomes to first-line pembrolizumab in patients with PD-L1-high (≥50%) non-small cell lung cancer and a poor performance status
Joao V Alessi, Biagio Ricciuti, Elizabeth Jiménez-Aguilar, et al.
Journal for Immunotherapy of Cancer
|
December 21, 2025
Multi-omics analysis reveals differential benefits of immunotherapy±chemotherapy based on detailed smoking history in advanced non-small cell lung cancer
Xinan Wang, Biagio Ricciuti, Arielle Elkrief, et al.
JTO Clinical and Research Reports
|
April 20, 2026
Efficacy of Adding Immune Checkpoint Inhibition to Chemotherapy, With or Without VEGF Inhibition, in Patients With Advanced <i>EGFR</i>-Mutated NSCLC: A Systematic Review and Meta-Analysis With Reconstructed Individual Patient Data
Alessandro Di Federico, Sara Stumpo, Linda Danielli, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
April 12, 2021
SMARCA4 and Other SWItch/Sucrose NonFermentable Family Genomic Alterations in NSCLC: Clinicopathologic Characteristics and Outcomes to Immune Checkpoint Inhibition
Joao V Alessi, Biagio Ricciuti, Liam F Spurr, et al.
The Lancet. Oncology
|
October 2, 2025
Long-term overall survival with dual CTLA-4 and PD-L1 or PD-1 blockade and biomarker-based subgroup analyses in patients with advanced non-small-cell lung cancer: a systematic review and reconstructed individual patient data meta-analysis
Alessandro Di Federico, Sara Stumpo, Francesco Mantuano, et al.
JCO Precision Oncology
|
February 8, 2024
Association of Baseline Tumor-Specific Neoantigens and CD8<sup>+</sup> T-Cell Infiltration With Immune-Related Adverse Events Secondary to Immune Checkpoint Inhibitors
Csaba Kerepesi, Hassan Mohammed Abushukair, Biagio Ricciuti, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
January 26, 2025
Gene Copy Deletion of STK11, KEAP1, and SMARCA4: Clinicopathologic Features and Association With the Outcomes of Immunotherapy With or Without Chemotherapy in Nonsquamous NSCLC
Malini M Gandhi, Arielle Elkrief, Catherine Gutierrez Moore, et al.
Cell Reports. Medicine
|
October 15, 2025
Pan-cancer spatial characterization of key immune biomarkers in the tumor microenvironment
James R Lindsay, Jennifer Altreuter, Joao V Alessi, et al.
Journal for Immunotherapy of Cancer
|
November 26, 2021
Low peripheral blood derived neutrophil-to-lymphocyte ratio (dNLR) is associated with increased tumor T-cell infiltration and favorable outcomes to first-line pembrolizumab in non-small cell lung cancer
Joao V Alessi, Biagio Ricciuti, Stephanie L Alden, et al.
Page
of 8